Major Depressive Disorder

Carmen Kosicek, MSN, PMHNP-BC; Charles Montano, MD; and Gus Alva, MD, DFAPA, provide take-home messages for the management of patients with MDD and other depressive disorders.

Experts in psychiatry examine emerging agents and unmet needs for the management of MDD.

"The history of medicine is rich in blaming the disease or the patient for 'untreatable' symptoms, until we stumble upon or develop a treatment that is, in fact, effective."

Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, comment on the impact of various classes of MDD treatments on time to achieve goals and/or response.

From special issues in diagnosing and treating catatonia to helping justice-involved individuals re-enter the community, here are highlights from the week in Psychiatric Times.

Carmen Kosicek, MSN, PMHNP-BC, leads a discussion on the level of satisfaction for both patients and providers with currently available MDD treatment options, barriers to access, and the impact of residual symptoms on a patient’s quality of life.

Experts in psychiatry share their treatment approaches for the management of episodic and chronic MDD.

Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, review currently available treatment options for the management of MDD and criteria used for treatment selection.

SPL026 with supportive therapy sees positive results in patients with major depressive disorder.

Catatonia: learn more about how to best diagnose early.

Is inflammation a biomarker of antidepressant efficacy? Researchers analyzed blood CRP levels as a predictor of response to antidepressants.

Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, provide advice regarding monitoring for adverse events and compliance with different classes of MDD treatment and review suggestions for follow-up and special patient populations.

Experts in psychiatry share their thoughts on the perception of MDD within the healthcare community and the implications of this condition being viewed as chronic vs episodic.

There may not be a diagnosis for ‘New Year Depression,’ about 10% to 20% of individuals in the US may get a milder form of these winter blues.

Metabolic depression? Researchers performed a metabolomic evaluation of patients with treatment-resistant depression.

From current treatments for cannabis use disorder to new possibilities for the treatment of dementia, here are highlights from the week in Psychiatric Times.

Carmen Kosicek, MSN, PMHNP-BC, and Charles Montano, MD, comment on the interplay between depression and other comorbid psychiatric and medical health conditions as well as the economic impact of MDD.

Charles Montano, MD; Carmen Kosicek, MSN, PMHNP-BC; and Gus Alva, MD, DFAPA, review the impact of the duration of MDD episodes and goals of managing episode recurrences.

Cariprazine is now FDA-approved as an adjunctive therapy to antidepressants.

From an in-depth analysis of ADHD in clinical practice to differences in effectiveness between intravenous and intranasal ketamine, here are highlights from the week in Psychiatric Times.

This latest submission completes the FDA filing that was initiated in May.

Does route of administration affect antidepressant efficacy of ketamine? Researchers performed a meta-analysis of trials comparing intravenous and intranasal administration.

Here’s why most of the claims recently made about antidepressants in Newsweek are wrong.

The first patient in a phase 2/3 study evaluating ulotaront for MDD has been enrolled.